Cost-Effectiveness Analysis of Anlotinib as Third- or Further-Line Treatment for Relapsed Small Cell Lung Cancer (SCLC) in China

被引：0
|
作者：
Jinhong Gong
Qian Wan
Jingjing Shang
Xiaodan Qian
Dan Su
Zhiqiang Sun
Guangjun Liu
机构：
[1] The Affiliated Changzhou No. 2 People’s Hospital of Nanjing Medical University,Department of Pharmacy
[2] Soochow University,Department of Pharmaceutics, College of Pharmaceutical Sciences
[3] Fudan University,Department of Pharmacy, Qingpu Branch of Zhongshan Hospital
[4] The Affiliated Changzhou No. 2 People’s Hospital of Nanjing Medical University,Department of Radiotherapy
来源：
Advances in Therapy | 2021年 / 38卷
关键词：
Anlotinib; Cost-effectiveness; SCLC; Targeted therapy; Third-line treatment;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：5116 / 5126
页数：10
相关论文
共 50 条
  • [1] Cost-Effectiveness Analysis of Anlotinib as Third- or Further-Line Treatment for Relapsed Small Cell Lung Cancer (SCLC) in China
    Gong, Jinhong
    Wan, Qian
    Shang, Jingjing
    Qian, Xiaodan
    Su, Dan
    Sun, Zhiqiang
    Liu, Guangjun
    ADVANCES IN THERAPY, 2021, 38 (10) : 5116 - 5126
  • [2] Cost-effectiveness analysis of anlotinib as a third-line or further treatment for advanced non-small cell lung cancer in China
    Zhu, Qiuyan
    Ni, Ronghua
    Guan, Xin
    TRANSLATIONAL LUNG CANCER RESEARCH, 2023, 12 (08) : 1782 - 1789
  • [3] Real-world efficacy and safety of anlotinib as third- or further-line treatment in refractory small cell lung cancer
    Gao, Xuetian
    Peng, Ling
    Zhang, Li
    Huang, Kai
    Yi, Cuihua
    Li, Bei
    Meng, Xue
    Li, Jisheng
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2022, 148 (10) : 2661 - 2671
  • [4] Real-world efficacy and safety of anlotinib as third- or further-line treatment in refractory small cell lung cancer
    Xuetian Gao
    Ling Peng
    Li Zhang
    Kai Huang
    Cuihua Yi
    Bei Li
    Xue Meng
    Jisheng Li
    Journal of Cancer Research and Clinical Oncology, 2022, 148 : 2661 - 2671
  • [5] Irinotecan monotherapy as third- or further-line treatment for patients with small cell lung cancer
    Seto, Zenta
    Takata, Naoki
    Murayama, Nozomu
    Tokui, Kotaro
    Okazawa, Seisuke
    Kambara, Kenta
    Imanishi, Shingo
    Miwa, Toshiro
    Hayashi, Ryuji
    Matsui, Shoko
    Inomata, Minehiko
    TUMORI JOURNAL, 2021, 107 (06): : 536 - 541
  • [6] Anlotinib as third- or further-line therapy for short-term relapsed small-cell lung cancer: subgroup analysis of a randomized phase 2 study (ALTER1202)
    Shi, Jianhua
    Cheng, Ying
    Wang, Qiming
    Li, Kai
    Wu, Lin
    Han, Baohui
    Chen, Gongyan
    He, Jianxing
    Wang, Jie
    Qin, Haifeng
    Li, Xiaoling
    FRONTIERS OF MEDICINE, 2022, 16 (05) : 766 - 772
  • [7] Cost-effectiveness of anlotinib vs. pembrolizumab and nivolumab as third-line treatment in recurrent small cell lung cancer in China
    Fei, Zhengyang
    Rui, Mingjun
    Wang, Yingcheng
    Ma, Aixia
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2023, 23 (01) : 79 - 87
  • [8] Anlotinib as Third-Line or Further-Line Treatment in Relapsed SCLC: A Multicentre, Randomized, DoubleBlind Phase 2 Trial
    Cheng, Y.
    Wang, Q.
    Li, K.
    Shi, J.
    Wu, L.
    Han, B.
    Chen, G.
    He, J.
    Wang, J.
    Qin, H.
    Li, X.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S351 - S352
  • [9] Anlotinib as third- or further-line therapy for short-term relapsed small-cell lung cancer: subgroup analysis of a randomized phase 2 study (ALTER1202)
    Jianhua Shi
    Ying Cheng
    Qiming Wang
    Kai Li
    Lin Wu
    Baohui Han
    Gongyan Chen
    Jianxing He
    Jie Wang
    Haifeng Qin
    Xiaoling Li
    Frontiers of Medicine, 2022, 16 : 766 - 772
  • [10] Third- and further-line therapy in advanced non-small-cell lung cancer patients: an overview
    Genestreti, Giovenzio
    Grossi, Francesco
    Genova, Carlo
    Burgio, Marco A.
    Bongiovanni, Alberto
    Gavelli, Giampaolo
    Bartolotti, Marco
    Di Battista, Monica
    Cavallo, Giovanna
    Brandes, Alba A.
    FUTURE ONCOLOGY, 2014, 10 (13) : 2081 - 2096
12345